SCHEMBL24050239

SCHEMBL24050239

O=S1(=O)N=C(NCc2ccc(OC(F)(F)F)cc2)Nc2ccc(Br)cc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.37
MAPK10 P53779 1/20 0.37
NTRK1 P04629 1/20 0.37
VNN1 O95497 2/20 0.36
KCNN3 Q9UGI6 1/20 0.36
PPARA Q07869 1/20 0.36
MAPK1 P28482 1/20 0.35
WDR5 P61964 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HTR2C P28335 1/20 0.35
CCNA2 P20248 1/20 0.34
CDK2 P24941 1/20 0.34
CCNA1 P78396 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC2 Q92769 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25327287 0.88 MAPK1 (0.42) MAPK8MAPK10NTRK1VNN1KCNN3
SCHEMBL24050851 0.88 CYP3A4 (0.44) NTRK1VNN1KCNN3PPARAMAPK1
SCHEMBL24050734 0.85 LMNA (0.43) MAPK8MAPK10NTRK1VNN1HTT
SCHEMBL24050529 0.82 KCNN3 (0.41) NTRK1VNN1KCNN3PPARASMN1; SMN2
SCHEMBL7952121 0.79 CA12 (0.40) SMN1; SMN2ALDH1A1
SCHEMBL24050236 0.73 NTRK1 (0.43) NTRK1P2RX7
SCHEMBL24050277 0.73 SMN1; SMN2 (0.50) VNN1HTTSMN1; SMN2ALDH1A1
SCHEMBL7954653 0.71 CA12 (0.46) SMN1; SMN2ALDH1A1
SCHEMBL24050282 0.71 ALDH1A1 (0.50) VNN1SMN1; SMN2ALDH1A1
SCHEMBL24050241 0.71 TAAR1 (0.45) SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219912-A1 HALOGENATED BENZOTHIADIAZINES FOR THE TREATMENT OF CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-07-13 US disclosed
US-20230219912-A1 HALOGENATED BENZOTHIADIAZINES FOR THE TREATMENT OF CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-07-13 US disclosed
WO-2021236818-A1 HALOGENATED BENZOTHIADIAZINES FOR THE TREATMENT OF CANCER BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2021-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219912-A1 HALOGENATED BENZOTHIADIAZINES FOR THE TREATMENT OF CANCER TFAM, NDUFAF1, NDUFV1 MAPK8 1948/4885MAPK10 2463/4885NTRK1 1890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.